drugset / Trial / NCT02254759
A Study of RO5186582 Treatment on Cytochrome P450 (CYP) 3A4 Activity in Healthy Participants
Non-randomizedCrossoverOpen-label
Summary
This is a non-randomized, open-label, five treatment, fixed sequence cross-over study to investigate the effect of RO5186582 treatment on CYP3A activity using midazolam as a probe CYP3A substrate, and also to assess the pharmacodynamic measures of brain electrical activity and sedation to explore the pharmacodynamic interaction between the gama-amino butyric acid (GABA)A negative allosteric modulator RO5186582 and the prototypical GABAA positive allosteric modulator midazolam. The anticipated study duration is up to nine weeks.
Timeline
- Start
- 2014-10
- Primary completion
- 2014-11
- Completion
- 2014-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Basmisanil | Small molecule | 240 mg | Oral |
| Subject | Midazolam | Small molecule | 1 mg | Intravenous |
| Subject | Midazolam | Small molecule | 5 mg | Oral |
Indications
No indication recorded.